Quick Answer
Oncotelic Therapeutics, Inc. reported Total Revenue of $70.0 thousand for fiscal year 2023.
Oncotelic Therapeutics, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $70.0K | — | — | $1.74M | — |
| Revenue (ASC 606) | — | — | — | — | $1.74M | — |
| Net Income | -$4.52M +42.8% |
-$7.90M -255.1% |
$5.09M +154.3% |
-$9.39M +1.2% |
-$9.50M -43.2% |
-$6.64M -831.3% |
| Diluted EPS | — | -$0.02 -300.0% |
$0.01 +133.3% |
-$0.03 | — | — |
| Total Assets | $26.68M -11.1% |
$30.01M -16.9% |
$36.12M +53.0% |
$23.61M -0.2% |
$23.66M -0.1% |
$23.68M +762.0% |
| Cash and Equivalents | — | $170.4K -29.4% |
$241.5K -57.5% |
$568.8K +20.0% |
$474.0K +478.3% |
$82.0K +3181.2% |
| Stockholders Equity | $8.25M -32.0% |
$12.13M -37.5% |
$19.41M +144.0% |
$7.96M -32.4% |
$11.77M -30.4% |
$16.90M +585.7% |
| R&D Expense | — | $61.1K -91.9% |
$756.9K -79.3% |
$3.66M -15.0% |
$4.30M +213.6% |
$1.37M +111.2% |
| Operating Income | -$3.58M +46.2% |
-$6.65M +31.6% |
-$9.72M -6.5% |
-$9.13M -20.3% |
-$7.58M -75.9% |
-$4.31M -504.8% |
| Shares Outstanding | 407.29M +2.0% |
399.18M +1.9% |
391.85M +4.4% |
375.29M +314.2% |
90.60M +7.8% |
84.07M +1128.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $70.0K | — | -95.0% |
| Revenue (ASC 606) | June 30, 2020 | $1.40M | — | +310.7% |
| Net Income | September 30, 2025 | -$1.05M | +68.3% | -476.9% |
| Diluted EPS | June 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $28.16M | +5.1% | +5.5% |
| Cash and Equivalents | September 30, 2025 | $409.0K | +174.5% | +364.7% |
| Stockholders Equity | September 30, 2025 | $9.05M | +2.2% | +9.0% |
| R&D Expense | June 30, 2025 | $297.00 | +17.9% | +0.0% |
| Operating Income | September 30, 2025 | -$491.0K | +85.0% | -644.2% |
| Shares Outstanding | September 30, 2025 | 439.45M | +7.9% | +7.6% |
- Oncotelic Therapeutics, Inc. reported Total Revenue of $70.0 thousand for fiscal year 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -96.0% in Total Revenue compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Revenue (ASC 606) of $1.74 million for fiscal year 2020.
- Oncotelic Therapeutics, Inc. reported Net Income of -$4.52 million for fiscal year 2024.
- Oncotelic Therapeutics, Inc. showed an increase of +42.8% in Net Income compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -300.0% in Diluted EPS compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Total Assets of $26.68 million for fiscal year 2024.
- Oncotelic Therapeutics, Inc. showed a decrease of -11.1% in Total Assets compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Cash and Equivalents of $170.4 thousand for fiscal year 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -29.4% in Cash and Equivalents compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Stockholders Equity of $8.25 million for fiscal year 2024.
- Oncotelic Therapeutics, Inc. showed a decrease of -32.0% in Stockholders Equity compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported R&D Expense of $61.1 thousand for fiscal year 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -91.9% in R&D Expense compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Operating Income of -$3.58 million for fiscal year 2024.
- Oncotelic Therapeutics, Inc. showed an increase of +46.2% in Operating Income compared to the prior fiscal year.
- Oncotelic Therapeutics, Inc. reported Shares Outstanding of 407.29 million shares for fiscal year 2024.
- Oncotelic Therapeutics, Inc. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: